SCHEMBL475787

SCHEMBL475787

C[C@@]1(F)C(=O)OC[C@@H](O)[C@H]1O

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.32
CYP3A4 P08684 3/20 0.32
MAPK1 P28482 3/20 0.32
HIF1A Q16665 2/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
PTPN1 P18031 2/20 0.32
NFKB1 P19838 1/20 0.32
THPO P40225 1/20 0.32
PPM1B O75688 1/20 0.32
PPP1CC P36873 1/20 0.32
TFPI2 P48307 1/20 0.32
PPP5C P53041 1/20 0.32
PPP2CA P67775 1/20 0.32
PPP1CA P62136 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GMNN O75496 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13204860 1.00 TP53 (0.32) TP53CYP3A4MAPK1HIF1ALMNA
SCHEMBL13204871 1.00 TP53 (0.32) TP53CYP3A4MAPK1HIF1ALMNA
SCHEMBL13222520 1.00 TP53 (0.32) TP53CYP3A4MAPK1HIF1ALMNA
SCHEMBL1034375 0.78
SCHEMBL1824543 0.77 TP53 (0.33) TP53CYP3A4MAPK1HIF1ALMNA
SCHEMBL5305197 0.77 TP53 (0.33) TP53CYP3A4MAPK1HIF1ALMNA
SCHEMBL5071496 0.68 CYP3A4 (0.31) CYP3A4
SCHEMBL10046442 0.67
SCHEMBL2971606 0.67
SCHEMBL13204847 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976382-B1 PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES IDENIX PHARMACEUTICALS INC (US) 2013-04-24 EP claimed
US-7781576-B2 Process for preparing a synthetic intermediate for preparation of branched nucleosides IDENIX PHARMACEUTICALS, INC. (US) 2010-08-24 US claimed
EP-1976382-A2 PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES IDENIX Pharmaceuticals, Inc. (US) 2008-10-08 EP claimed
WO-2007075876-A2 PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES IDENIX PHARMACEUTICALS, INC. (US) 2007-07-05 WO claimed
US-10577359-B2 Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives GILEAD PHARMASSET LLC (US) 2020-03-03 US disclosed
EP-1809301-B1 2-FLUORO-2-ALKYL-SUBSTITUTED D-RIBONOLACTONE INTERMEDIATES GILEAD PHARMASSET LLC (US) 2019-11-06 EP disclosed
US-20170253584-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES GILEAD PHARMASSET LLC (US) 2017-09-07 US disclosed
EP-3109244-A2 PREPARATION OF 2'FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES Gilead Pharmasset LLC (US) 2016-12-28 EP disclosed
US-20160024061-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET, INC. 2016-01-28 US disclosed
CN-102199181-B Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives GILEAD PHARMASSET LLC 2014-09-17 CN disclosed
US-20130338349-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET, INC. 2013-12-19 US disclosed
US-8492539-B2 Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives GILEAD PHARMASSET LLC (US) 2013-07-23 US disclosed
EP-1773856-A2 PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES Pharmasset, Inc. (US) 2007-04-18 EP disclosed
US-20060199783-A1 Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives PHARMASSETT, INC. (US) 2006-09-07 US disclosed
US-20060199783-A1 Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives PHARMASSETT, INC. (US) 2006-09-07 US disclosed
WO-2006012440-A3 PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET INC (US) 2006-07-27 WO disclosed
US-20060122146-A1 Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives GILEAD SCIENCES, INC. 2006-06-08 US disclosed
WO-2006031725-A2 PREPARATION OF 2'­FLUORO-2'- ALKYL- SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET, INC. (US) 2006-03-23 WO disclosed
WO-2006012440-A2 PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET, INC. (US) 2006-02-02 WO disclosed
WO-2006012440-A2 PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES PHARMASSET, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199783-A1 Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives NSUN2, FBL, UMPS TP53 2800/4885CYP3A4 863/4885MAPK1 3063/4885
US-20160024061-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES NSUN2, FBL, RNGTT TP53 2566/4885CYP3A4 821/4885MAPK1 3198/4885
US-20170253584-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES NSUN2, FBL, RNGTT TP53 2508/4885CYP3A4 842/4885MAPK1 3193/4885
US-10577359-B2 Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives NSUN2, FBL, RNGTT TP53 2634/4885CYP3A4 836/4885MAPK1 3158/4885
US-20060122146-A1 Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives NSUN2, FBL, RNGTT TP53 2508/4885CYP3A4 842/4885MAPK1 3193/4885
US-20130338349-A1 PREPARATION OF 2'-FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES NSUN2, FBL, RNGTT TP53 2508/4885CYP3A4 842/4885MAPK1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.